Multiple studies (Hauschild et al., 2018; Long et al., 2018; Planchard et al., 2016) found that the first combined BRAF and MEK inhibitors therapy showed significant improvement in an investigator-assessed overall response and relapse-free survival in treating melanoma, which led to global approval. This evidence concerns the gene MAP2K7 and melanoma.